-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
There are about 2 million ischemic strokes worldwide each year without a clear cause.
These strokes are classified as cryptogenic strokes, accounting for about 17% of all ischemic strokes
.
Cryptogenic stroke is called embolic stroke of unknown origin (ESU)
There are about 2 million ischemic strokes worldwide each year without a clear cause.
Although uncommon, cardiac embolism and subsequent stroke caused by the left ventricle (LV) have several recognized sources, such as recent acute myocardial infarction or severe LV systolic dysfunction
A special exploratory analysis was performed on the data of the new method rivaroxaban in the global trial of inhibiting factor Xa and aspirin to prevent embolism in ESUS (Navigation ESUS).
This is a randomized phase 3 clinical trial from December 2014 Register until September 2017
.
The research background includes 459 stroke recruitment centers in 31 countries
A special exploratory analysis was performed on the data of the new method rivaroxaban in the global trial of inhibiting factor Xa and aspirin to prevent embolism in ESUS (Navigation ESUS).
Participants were randomly assigned to take 15 mg rivaroxaban or 100 mg aspirin daily
This study tested whether rivaroxaban is superior to aspirin in reducing the following risks:
(1) The main results of repeated strokes or systemic embolism;
(1) The main results of repeated strokes or systemic embolism;(2) average 10.
4 months of follow-up, again stroke, systemic embolism, myocardial infarction, or heart vascular test secondary outcomes of death
.
4 months of follow-up, again stroke, systemic embolism, myocardial infarction, or heart vascular test secondary outcomes of death
.
Heart blood vessels
Local left ventricular dysfunction is determined by echocardiography, which is defined as moderate to severe damage to the overall systolic function of the left ventricle and/or local ventricular wall motion abnormalities
.
The Cox proportional hazards model was used to evaluate the treatment interaction, and the risk ratio of randomly taking rivaroxaban to aspirin was estimated based on the status of left ventricular dysfunction
Local left ventricular dysfunction is determined by echocardiography, which is defined as moderate to severe damage to the overall systolic function of the left ventricle and/or local ventricular wall motion abnormalities
- 502 participants (7.
1%) had left ventricular dysfunction
.
Among the participants with left ventricular dysfunction, the average age was 67 years (10 years), and 130 of them were women (26%)
In this particular exploratory analysis, rivaroxaban was more effective than aspirin in reducing the risk of stroke or systemic embolism in participants with left ventricular dysfunction
Literature source: https://jamanetwork-com.
fjny.
80599.
net/journals/jamaneurology/article-abstract/2785030 https://jamanetwork-com.
fjny.
80599.
net/journals/jamaneurology/article-abstract/2785030 in This message
